perspective on H7N9

Top of Form

Global
Concerns Regarding Novel Influenza A (H7N9) Virus Infections

Timothy M. Uyeki,
M.D., M.P.H., M.P.P., and Nancy J. Cox, Ph.D.

April 11, 2013DOI: 10.1056/NEJMp1304661

Severe disease in
humans caused by a novel influenza A virus that is distinct from circulating
human influenza A viruses is a seminal event. It might herald sporadic human
infections from an animal source — e.g., highly pathogenic avian influenza
(HPAI) A (H5N1) virus; or it might signal the start of an influenza pandemic —
e.g., influenza A(H1N1)pdm09 virus. Therefore, the discovery of novel influenza
A (H7N9) virus infections in three critically ill patients reported in the Journal
by Gao and colleagues is of major public health significance. Chinese
scientists are to be congratulated for the apparent speed with which the H7N9
virus was identified, and whole viral genome sequences were made publicly
available in relatively short order. Because this H7N9 virus has not been
detected in humans or animals previously, the situation raises many urgent
questions and global public health concerns.

The key question for
pandemic risk assessment is whether there is evidence of either limited or,
more important, sustained human-to-human transmission — the latter being
indicative of an emerging pandemic. If human-to-human transmission occurs,
transmission dynamics, modes of transmission, basic reproductive number, and
incubation period must all be determined. It is possible that these severely
ill patients represent the tip of the iceberg and that there are many more
as-yet-undetected mild and asymptomatic infections. Determining the spectrum of
illness will help us understand the scope of the problem and assess severity.
Enhanced surveillance for H7N9 virus infection is therefore urgently needed
among hospitalized patients and outpatients of all ages with less severe
respiratory illness. Other useful information can be derived from monitoring
close contacts of patients with confirmed H7N9 cases to assess whether family
members or health care personnel who provided care for patients with H7N9 virus
infection have respiratory illness and laboratory-confirmed H7N9 virus
infection. Such investigations will clarify whether H7N9 virus transmission in
people appears efficient, or whether limited, nonsustained human-to-human
transmission is occurring in persons with prolonged unprotected exposures, such
as in clusters of HPAI H5N1 cases in blood-related family members. So far, the
information provided by Chinese health officials provides reassurance that
sustained human-to-human transmission is not occurring.

In addition to causing
severe illness and deaths, the novel H7N9 viruses reported by Gao and
colleagues have genetic characteristics that are of concern for public health.
The hemagglutinin (HA) sequence data suggest that these H7N9 viruses are a
low-pathogenic avian influenza A virus and that infection of wild birds and
domestic poultry would therefore result in asymptomatic or mild avian disease,
potentially leading to a “silent” widespread epizootic in China and neighboring
countries. If H7N9 virus infection is primarily zoonotic, as reports currently
suggest, transmission is expected to occur through exposure to clinically
normal but infected poultry, in contrast to HPAI H5N1 virus infection, which
typically causes rapid death in infected chickens.

The gene sequences
also indicate that these viruses may be better adapted than other avian
influenza viruses to infecting mammals. For example, the presence of Q226L in
the HA protein has been associated with reduced binding to avian-like receptors
bearing sialic acids linked to galactose by α-2,3 linkages found in the human
lower respiratory tract,1 and
potentially an enhanced ability to bind to mammalian-like receptors bearing
sialic acids linked to galactose by α-2,6 linkages located in the human upper
airway.1
Equally troubling is that Q226L in HA has been shown to be associated with
transmission of HPAI H5N1 viruses by respiratory droplets in ferrets, one of
the animal models for assessing pathogenicity and transmissibility of influenza
viruses.2,3
These H7N9 viruses also possess the E627K substitution in the PB2 protein,
which has also been associated with mammalian adaptation and
respiratory-droplet transmission of HPAI H5N1 virus in ferrets.3
This H7N9 virus is a novel reassortant with HA and neuraminidase (NA) genes
from an ancestral avian H7N9 virus and the six other genes from an avian H9N2
virus. The animal reservoir now appears to be birds, but many experts are
asking whether these viruses might also be able to infect pigs, another common
reservoir for zoonotic infections. The viral sequence data indicate antiviral
resistance to the adamantanes and susceptibility to neuraminidase inhibitors,
except for a 292K mutation in the NA protein of the A/Shanghai/1/2012 virus.
Because this mutation has been associated with in vitro resistance to
neuraminidase inhibitors in another N9 NA subtype virus, additional analyses
must be undertaken to understand its significance. It is not known whether this
mutation arose de novo in the host or is associated with oseltamivir treatment.
Ongoing surveillance is crucial to assessing the emergence and prevalence of
H7N9 viruses resistant to available antivirals.

Since available
diagnostic assays used in clinical care (e.g., rapid influenza diagnostic
tests) may lack sensitivity to identify H7N9 virus and since existing molecular
assays will identify H7N9 virus as a nonsubtypeable influenza A virus, a
critical public health issue is the rapid development, validation, and
deployment of molecular diagnostic assays that can specifically detect H7N9
viral RNA. Such assays have been developed in China and are in development in
many countries including the United States, and they will be deployed as they
were for the 2009 H1N1 pandemic.4
Having available H7-specific assays will facilitate surveillance of H7N9 virus
infections and help address key questions such as the duration of viral
shedding, the infectious period, the optimal clinical specimens for laboratory
confirmation, and the spectrum of clinical illness.

The clinical features
described in the three patients with H7N9 virus infection, including fulminant
pneumonia, respiratory failure, acute respiratory distress syndrome (ARDS),
septic shock, multiorgan failure, rhabdomyolysis, and encephalopathy, are very
troubling. Clinical care of severely ill patients should be focused on
evidence-based supportive management of complications such as ARDS. Adherence
to recommended infection-control measures in clinical settings to reduce the
risk of nosocomial transmission cannot be overemphasized.

All three patients
with H7N9 virus infection reported by Gao and colleagues received late
treatment with oseltamivir starting on day 7 or 8 of illness while critically
ill. Data related to human infections with seasonal, pandemic, and HPAI H5N1
viruses indicate that the earlier antiviral treatment is initiated, the greater
the clinical benefit. Therefore, oral oseltamivir or inhaled zanamivir should
be administered to patients with suspected or confirmed H7N9 virus infection as
soon as possible. Secondary invasive bacterial infections associated with
influenza can cause severe and fatal complications, and appropriate empirical
antibiotic treatment for community-acquired bacterial infections may be
indicated for initial management of severe H7N9 pneumonia. Caution should be
exercised regarding the use of glucocorticoids, which are not indicated for
routine treatment of influenza. Clinical research, including randomized, controlled
trials and observational studies, is urgently needed on new antiviral agents,
including parenteral neuraminidase inhibitors and drugs with different
mechanisms of action, combination antiviral treatment, and immunotherapy. To
inform clinical management, rapid clinical data collection, data sharing,
analysis, and timely feedback are needed worldwide.5

Because H7N9 virus
infections have not occurred in humans before, it is expected that persons of
all ages might be susceptible worldwide. Serologic assays must be developed so
that studies can be conducted to determine whether some people have
cross-reactive antibodies to these viruses from prior influenza A virus infections.
Existing H7-vaccine viruses are not well matched to this novel H7N9 virus, and
extensive efforts are under way to develop potential H7N9 vaccines as quickly
as possible. These efforts have started worldwide using the H7N9 sequence data
obtained from these early cases, and sharing of H7N9 viruses will further
facilitate vaccine development. There are many challenges to making H7N9
vaccines available. Previously studied H7 vaccines were poorly immunogenic in
humans, and clinical trials to assess the safety and immunogenicity of H7N9
vaccine candidates will be needed. But even if new vaccine manufacturing
technologies, such as tissue-cell-culture–derived vaccine antigens, are
utilized, the process from vaccine development to availability will probably take
many months.

The 2009 H1N1 pandemic
taught us many lessons, including that a pandemic virus can emerge from an
animal reservoir in an unexpected location and be spread rapidly through air
travel. The focus on critically ill adults early in the pandemic led to
elevated public concern about pandemic severity. Clear communication of key
messages to the public and the clinical community is critical in implementing
successful prevention and control activities. The detection of human H7N9 virus
infections is yet another reminder that we must continue to prepare for the
next influenza pandemic. The coming weeks will reveal whether the epidemiology
reflects only a widespread zoonosis, whether an H7N9 pandemic is beginning, or
something in between. The key is intensified surveillance for H7N9 virus in
humans and animals to help answer important questions. We cannot rest our
guard.